BBNX Stock Beta Bionics, Inc.
STRONG BUY US · NasdaqGMInitiation coverage and category momentum make this an emerging commercial growth story.
Future value: $24.24 (+18.20%) · 6-12 months · analyst consensus
Signal breakdown
- ▸New analyst initiation supports early momentum.
- ▸Above 50-day MA (+7.07%)
- ▸Above 200-day MA — long-term uptrend
Is BBNX a buy right now?
Trend: BBNX is trading above the 50-day average (+7.05%), RSI 39 — neutral momentum, with a 3-month return of +29.81%.
Valuation & quality: Beta Bionics, Inc. trades on forward P/E -9.5, price-to-book 3.60; fundamentals show net margin -61.3%, return on equity -26.2%, revenue growth 37.8% year on year.
Analyst consensus: 14 analysts have a mean 12-month price target of $24.24 (+18.2% vs the last close; range $16.00 – $30.40), consensus rating “buy”.
Our screen: STRONG BUY (score 4) — Initiation coverage and category momentum make this an emerging commercial growth story.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -20.70% | +1.80% | +18.80% | +29.30% | -18.10% | +55.50% | -4.90% | +8.10% |
Fundamentals
Analyst price target
Technical signals
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
Sector: Healthcare · Industry: Medical Devices · United States · 420 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.